Lump sum or DCA, the latest on Ozempic & a baby Berkshire?

Equity Mates Investing Podcast · Mar 31, 2024 · 30m

Haven't heard much about Ozempic lately? Let us change that and bring you up to speed on some wild developments in the world of weight loss drugs.

In this episode we cover:

How Novo Nordisk's latest drug has been twice as effective as their existing drugs in early trials

The growing list of competitors to Ozempic

Why these drugs could be incredible technology but less-than-incredible investments from here

A new company trying to copy Berkshire Hathaway's playbook

The impressive first 20 years of this company's Berkshire-lite playbook

We answer the age-old question: should I invest in a lump…